<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kuznar, Wayne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Strand, Vibeke</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">GR Agonist Improves Responses in RA</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">8-9</style></pages><abstract><style  face="normal" font="default" size="100%">The glucocorticoid receptor (GR) regulates genes that control development and metabolism and the immune response. A dissociated agonist of the glucocorticoid receptor (DAGR) is a nonsteroidal ligand of the GR that has both partial agonist and antagonistic properties. This article discusses a phase 2 trial that compared response rates between a DAGR and prednisone in patients with rheumatoid arthritis.</style></abstract><number><style face="normal" font="default" size="100%">51</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>